诺和诺德12月9日宣布已成功完成对生物制药公司Akero Therapeutics的收购。此次收购以每股54美元现金（总价值达47亿美元）及一项不可转让的或有价值权（CVR）作为交易对价，全面收购了Akero所有已发行的普通股及等价物。随着交易的圆满结束，Akero正式成为诺和诺德旗下的全资子公司，其普通股也将随之从纳斯达克全球精选市场退市，不再进行上市交易。
Source Link诺和诺德12月9日宣布已成功完成对生物制药公司Akero Therapeutics的收购。此次收购以每股54美元现金（总价值达47亿美元）及一项不可转让的或有价值权（CVR）作为交易对价，全面收购了Akero所有已发行的普通股及等价物。随着交易的圆满结束，Akero正式成为诺和诺德旗下的全资子公司，其普通股也将随之从纳斯达克全球精选市场退市，不再进行上市交易。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.